◎ Sugi Atlas

Atlas / Drug / Lactoferrin, Bovine

Lactoferrin, Bovine

drug
On this page

Also known as Bovine lactoferrinCows milk-derived lactoferrinLactoferrinbovine

Summary

Lactoferrin, Bovine (CHEMBL5095320) is a phase-3 clinical-stage unknown targeting NPY1R and NPY4R; indicated across 4 conditions including urinary tract infection and diarrheal disease.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Targets: 2 (NPY1R, NPY4R)
  • Indications: 4 conditions
  • Clinical trials: 13

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL5095320
NameLactoferrin, Bovine
TypeUnknown
Max phase3

Also known as: Bovine lactoferrin, Cows milk-derived lactoferrin, Lactoferrin, bovine, LACTOFERRIN, BOVINE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NPY1RY1 receptorFull agonist7.90.5%P25929
NPY4RY4 receptorFull agonist8.640%P50391

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): NPY1R, NPY4R.

Top Reactome pathways

2 total, by targets touching each:

PathwayTargetsGenes
Peptide ligand-binding receptors2NPY1R, NPY4R
G alpha (i) signalling events2NPY1R, NPY4R

Dominant GO biological processes

GO termTargets
cell communication2
signal transduction2
G protein-coupled receptor signaling pathway2
neuropeptide signaling pathway2
signaling2
outflow tract morphogenesis1
glucose metabolic process1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway1
locomotory behavior1
feeding behavior1
regulation of blood pressure1
sensory perception of pain1
regulation of multicellular organism growth1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
urinary tract infection3MONDO:0100338EFO:0003103
diarrheal disease2MONDO:0001673HP:0002014
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

PhaseTrials
Not specified7
PHASE34
PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00560222PHASE3COMPLETEDRandomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children
NCT01525316PHASE3COMPLETEDLactoferrin for Prevention of Sepsis in Infants
NCT03367013PHASE3COMPLETEDLactoferrin Infant Feeding Trial - LIFT_Canada
NCT06109688PHASE3COMPLETEDEffect of Lactoferrin Supplementation on Urinary Tract Infections in Infants.
NCT02626104PHASE2COMPLETEDBovine Lactoferrin and Antibiotic-associated Diarrhoea.
NCT04526821PHASE2TERMINATEDLactoferrin for Prevention of COVID-19 in Health Care Workers
NCT01535170Not specifiedUNKNOWNBovine Lactoferrin as a Natural Regimen of Selective Decontamination of the Digestive Tract in Patients With Prolonged Mechanical Ventilation
NCT01596634Not specifiedCOMPLETEDBovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy
NCT03558789Not specifiedCOMPLETEDMetallic Taste Before, During and After Treatment of Head and Neck Cancer
NCT03866837Not specifiedCOMPLETEDPrebiotic GOS and Lactoferrin With Iron Supplements
NCT04432935Not specifiedCOMPLETEDEffect of Lactoferrin on Polio Seroconversion
NCT04847791Not specifiedUNKNOWNLactoferrin in Covid-19 Hospitalized Patients
NCT06015828Not specifiedCOMPLETEDEffect of Enteral Bovine Lactoferrin in Preterm Infants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

124 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
PANCREATIC POLYPEPTIDEChEMBLPhase 2NPY1R, NPY4R
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)NPY1R
RIFAMPINChEMBL + PubChemPhase 4 (approved)NPY1R
TEGASERODChEMBL + PubChemPhase 4 (approved)NPY1R
AMSACRINEChEMBLPhase 4 (approved)NPY1R
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NPY1R
CARVEDILOLChEMBLPhase 4 (approved)NPY1R
CHLORHEXIDINEChEMBLPhase 4 (approved)NPY1R
ECONAZOLE NITRATEChEMBLPhase 4 (approved)NPY1R
FENTICONAZOLEChEMBLPhase 4 (approved)NPY1R
HEXACHLOROPHENEChEMBLPhase 4 (approved)NPY1R
LANSOPRAZOLEChEMBLPhase 4 (approved)NPY1R
LASOFOXIFENEChEMBLPhase 4 (approved)NPY1R
METOPROLOLChEMBLPhase 4 (approved)NPY1R
MITOXANTRONEChEMBLPhase 4 (approved)NPY1R
NEBIVOLOLChEMBLPhase 4 (approved)NPY1R
NITAZOXANIDEChEMBLPhase 4 (approved)NPY1R
PYRVINIUMChEMBLPhase 4 (approved)NPY1R
RABEPRAZOLEChEMBLPhase 4 (approved)NPY1R
RIFAXIMINChEMBLPhase 4 (approved)NPY1R
SUNITINIBChEMBLPhase 4 (approved)NPY1R
TAMOXIFENChEMBLPhase 4 (approved)NPY1R
TERFENADINEChEMBLPhase 4 (approved)NPY1R
THIORIDAZINEChEMBLPhase 4 (approved)NPY1R
TRIFLUOPERAZINEChEMBLPhase 4 (approved)NPY1R
BENSERAZIDEChEMBLPhase 3NPY1R
NAFAMOSTATChEMBLPhase 3NPY1R
OTILONIUM BROMIDEChEMBLPhase 3NPY1R
BENZETHONIUMChEMBLPhase 2NPY1R
DOMIPHENChEMBLPhase 2NPY1R
AbirateronePubChemApprovedNPY1R
AcebutololPubChemApprovedNPY1R
AcetazolamidePubChemApprovedNPY1R
AcetylcholinePubChemApprovedNPY1R
acetylcysteinePubChemApprovedNPY1R
Aclidinium BromidePubChemApprovedNPY1R
AcyclovirPubChemApprovedNPY1R
AdeninePubChemApprovedNPY1R
AfatinibPubChemApprovedNPY1R
AlbendazolePubChemApprovedNPY1R
albuterolPubChemApprovedNPY1R
Alendronic AcidPubChemApprovedNPY1R
AlfuzosinPubChemApprovedNPY1R
AllopurinolPubChemApprovedNPY1R
AlmotriptanPubChemApprovedNPY1R
AlogliptinPubChemApprovedNPY1R
AlosetronPubChemApprovedNPY1R
AlprazolamPubChemApprovedNPY1R
AmantadinePubChemApprovedNPY1R
AmiloridePubChemApprovedNPY1R
aminolevulinic acidPubChemApprovedNPY1R
AmiodaronePubChemApprovedNPY1R
AmisulpridePubChemApprovedNPY1R
AmitriptylinePubChemApprovedNPY1R
AmlodipinePubChemApprovedNPY1R
AmoxapinePubChemApprovedNPY1R
AnagrelidePubChemApprovedNPY1R
AntipyrinePubChemApprovedNPY1R
ApixabanPubChemApprovedNPY1R
AprepitantPubChemApprovedNPY1R

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot